Overview

BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis

Status:
Completed

Trial end date:
2017-08-01

Target enrollment:

Participant gender:

Summary

This is a randomized double blind, double dummy, active comparator controlled, parallel design study that is performed to assess the safety and efficacy of BI 655066/ABBV-066 (risankizumab) compared to adalimumab to support registration for the treatment of moderate to severe chronic plaque psoriasis in adult patients.

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie

Collaborator:

Boehringer Ingelheim

Treatments:

Adalimumab
Antibodies, Monoclonal